CB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting
April 20 2017 - 10:33AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced
that clinical data for its drug candidate CB-1158, an orally
bioavailable arginase inhibitor, will be presented at the 53rd
Annual Meeting of the American Society of Clinical Oncology (ASCO),
which is being held from June 2 to June 6, 2017 in Chicago,
Illinois. Clinical results to be presented include
monotherapy data from Calithera’s Phase I trial in solid tumors.
CB-1158 is being developed in collaboration with Incyte
Corporation.
CX-1158-101: A first-in-human phase 1 study of CB-1158,
a small molecule inhibitor of arginase, as monotherapy and in
combination with an anti-PD-1 checkpoint inhibitor in patients with
solid tumors.Abstract #3005Presenter: Kyriakos
Papadopoulos MD, South Texas Accelerated Research TherapeuticsDate:
June 5, 2017Session: 1:15 p.m. – 4:15 p.m. CT, Developmental
Therapeutics-Immunology, Hall D1
About ArginaseArginase is an enzyme produced by
immunosuppressive myeloid cells, including myeloid-derived
suppressor cells (MDSCs) and neutrophils, which prevents T-cell and
natural killer (NK) cell activation in tumors. Arginase exerts its
immunosuppressive effect by depleting the amino acid arginine in
the tumor microenvironment which subsequently prevents activation
and proliferation of the immune system’s cytotoxic T-cells and
NK-cells. Inhibition of arginase activity reverses this
immunosuppressive block and restores T-cell function. In
preclinical models, arginase inhibition has been shown to enhance
anti-tumor immunity and inhibit tumor growth.
About Calithera Calithera Biosciences, Inc. is
a clinical-stage pharmaceutical company focused on discovering and
developing novel small molecule drugs directed against tumor
metabolism and tumor immunology targets for the treatment of
cancer. Calithera’s lead product candidate, CB-839, is a
potent, selective, reversible and orally bioavailable inhibitor of
glutaminase. CB-839 takes advantage of the pronounced dependency
many cancers have on the nutrient glutamine for growth and
survival. It is currently being evaluated in Phase 1/2 clinical
trials in combination with standard of care agents. CB-1158
is a first-in-class immuno-oncology metabolic checkpoint inhibitor
targeting arginase, a critical immunosuppressive enzyme responsible
for T-cell suppression by myeloid-derived suppressor cells.
Arginase depletes arginine, a nutrient that is critical for the
activation, growth and survival of the body’s cancer-fighting
immune cells, known as cytotoxic T-cells. CB-1158 is
currently in a Phase I clinical trial. Calithera is
headquartered in South San Francisco, California. For more
information about Calithera, please visit www.calithera.com.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
"may," "will," "expect," "anticipate," "estimate," "intend,"
"poised" and similar expressions (as well as other words or
expressions referencing future events, conditions, or
circumstances) are intended to identify forward-looking
statements. These statements include those related to the
Company’s clinical pipeline of novel cancer therapies.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. The potential
product candidates that Calithera develops may not progress through
clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials
may not confirm any safety, potency or other product
characteristics described or assumed in this press release.
Such product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations
with respect to any of the foregoing matters may have a negative
effect on Calithera's stock price. Additional information
concerning these and other risk factors affecting Calithera's
business can be found in Calithera's most recent Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission, and
other periodic filings with the Securities and Exchange Commission
at www.sec.gov. These forward-looking statements are not guarantees
of future performance and speak only as of the date hereof, and,
except as required by law, Calithera disclaims any obligation to
update these forward-looking statements to reflect future events or
circumstances.
Contact:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024